3VS: Prototyping and validation of a vesicular nanotechnological device for gene therapy alternative to viral vectors.
This project was based on the patent “Method for obtaining concentrated populations of extracellular vesicles (EVs) washed of physiopathological load thereof”, WO2023/073609A1. The aim of the project was the encapsulation of a plasmid DNA inside lymphocytes-derived EVs, osmotically lysed using the method described in the patent. The efficacy and safety of this new vesicular viral vector substitute was compared with more traditional methods of gene transfer such as non-liposomal lipids and lentiviral vectors for the treatment of multiple myeloma.
